Evidence map›Paper›PMID 37387358›Full record

Trial reportDiabetes & vascular disease research

Cardiometabolic risk factors, peripheral arterial tonometry and metformin in adults with type 1 diabetes participating in the REducing with MetfOrmin Vascular Adverse Lesions trial.

David Chen, Alicia J Jenkins, Nicola Greenlaw, Katie Dudman, Tamsin Fernandes, David M Carty, Alun D Hughes, Andrzej S Januszewski, Coen DA Stehouwer, John R Petrie

Open access · diamondAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetes & vascular disease research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

David ChenNational Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.ORCID 0000-0001-6298-3645
Alicia J JenkinsNational Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
Nicola GreenlawRobertson Centre for Biostatistics, School of Health and Wellbeing, University of Glasgow, Glasgow, UK.
Katie DudmanRobertson Centre for Biostatistics, School of Health and Wellbeing, University of Glasgow, Glasgow, UK.
Tamsin FernandesInstitute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
David M CartyInstitute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
Alun D HughesInstitute of Cardiovascular Science, University College London, London, UK.
Andrzej S JanuszewskiNational Health and Medical Research Council Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
Coen DA StehouwerDepartment of Internal Medicine and Cardiovascular Research Institute Maastricht, Maastricht University Medical Centre, Maastricht, Netherlands.
John R PetrieRobertson Centre for Biostatistics, School of Health and Wellbeing, University of Glasgow, Glasgow, UK.
University of Glasgow · GBThe University of Sydney · AUMaastricht University Medical Centre · NLUniversity College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPeripheral arterial tonometry (PAT) provides non-invasive measures of vascular health. Beneficial effects of metformin on vascular function have been reported in youth with type 1 diabetes (T1D). In the REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL) trial in adults with T1D and high cardiovascular risk, we examined: (i) the extent to which routinely-measured cardiometabolic risk factors explain variance in baseline PAT; and (ii) the effects of metformin on PAT measures.

methodsCross-sectional univariable and multivariable analyses of baseline reactive hyperaemia index (RHI) and augmentation index (AI) (EndoPAT® (Itamar, Israel); and analysis of 36-months metformin versus placebo on vascular tonometry.

resultsIn 364 adults ((mean ± SD) age 55.2 ± 8.5 years, T1D 34.0 ± 10.6 years, HbA1c 64.5 ± 9.0 mmol/mol (8.1 ± 0.8%)), RHI was 2.26 ± 0.74 and AI was 15.9 ± 19.2%. In an exhaustive search, independent associates of (i) RHI were smoking, waist circumference, systolic blood pressure and vitamin B12 (adjusted

conclusionCardiometabolic risk factors explained only a modest proportion of variance in PAT measures of vascular health in adults with T1D and high cardiovascular risk. PAT measures were not affected by metformin.

Indexed as

Diabetes Mellitus, Type 1MetforminAdultArteriesCardiometabolic Risk FactorsCross-Sectional StudiesFemaleHumansMaleMiddle AgedMetforminAugmentation indexmetforminreactive hyperaemia indextonometrytype 1 diabetesvascular function

Identifiers

PMID37387358
PMCPMC10328035
OpenAlexW4382631736

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.